Genomics Bioscience & Technology Co

Genomics Bioscience & Technology Co CapEx/D&A

The CapEx to Depreciation Ratio of Genomics Bioscience & Technology Co (4195.TWO) as of Nov 3, 2026 is 291.74. In the previous year, CapEx to Depreciation Ratio was 346.38 — a change of -15.77% (lower).

CapEx/D&A

291.74

YoY

-15.77%

Last updated:

CapEx to Depreciation Ratio of Genomics Bioscience & Technology Co is 2024 291.74 . CapEx to Depreciation Ratio of Genomics Bioscience & Technology Co was 2023 346.38 . It decreases by -15.77% lower compared to the previous year.

The Genomics Bioscience & Technology Co CapEx/D&A history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

CapEx/D&A
Date
CapEx/D&A
Jan 1, 2017
10.13 TWD
Jan 1, 2018
3.23 TWD
Jan 1, 2019
4.74 TWD
Jan 1, 2020
188.77 TWD
Jan 1, 2021
206.12 TWD
Jan 1, 2022
288.17 TWD
Jan 1, 2023
346.38 TWD
Jan 1, 2024
291.74 TWD
The Genomics Bioscience & Technology Co CapEx/D&A history
YEARCapEx/D&AYoY
291.74-15.77%
346.38+20.20%
288.17+39.81%
206.12+9.19%
188.77+3,881.79%
4.74+46.57%
3.23-68.07%
10.13+8.41%
9.34+7.81%
8.67-88.11%
72.91—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Genomics Bioscience & Technology Co Stock analysis

What does Genomics Bioscience & Technology Co do? Genomics BioSci & Tech.Co., Ltd. generates revenue through the provision of public gene sequencing and clinical sequencing services, including preventive genetic testing, primer synthesis, and individualized medical and genetic screening for cancers. The company also manufactures and sells biochemical instruments, reagents, and consumables, distributing these products domestically and internationally. Its primary customers are healthcare providers and research institutions seeking genetic analysis and diagnostic solutions. The firm's services and products target both public health initiatives and specialized medical applications in oncology and preventive care. The company's revenue streams are derived from its core biotechnological services and product sales, with a focus on domestic and overseas markets. Public gene sequencing services cater to broader health screening needs, while clinical sequencing services address specific medical conditions, particularly cancer-related genetic screening. The firm's biochemical instruments and reagents support laboratory operations in both research and clinical settings, serving a diverse clientele across multiple healthcare segments. Genomics Bioscience & Technology Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Genomics Bioscience & Technology Co stock

CapEx to Depreciation Ratio of Genomics Bioscience & Technology Co is 291.74 in 2024.

CapEx to Depreciation Ratio of Genomics Bioscience & Technology Co changed from 346.38 to 291.74, representing a -15.77% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of CapEx to Depreciation Ratio Genomics Bioscience & Technology Co since 2006 – with annual values, charts, and detailed analysis.

The CapEx/D&A ratio compares investment spending to asset depreciation. Ratios above 1.0x indicate the company is growing its asset base, below 1.0x suggests underinvestment.

A 'good' varies by industry and company stage. On Eulerpool, you can compare CapEx to Depreciation Ratio's Genomics Bioscience & Technology Co with sector peers and the industry average to assess whether it is attractive.

To evaluate CapEx to Depreciation Ratio's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for CapEx to Depreciation Ratio.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Genomics Bioscience & Technology Co

All Key Metrics — Genomics Bioscience & Technology Co